Vertex Pharmaceuticals Inc (VRTX)
445.21
+4.57
(+1.04%)
USD |
NASDAQ |
May 17, 16:00
445.28
+0.08
(+0.02%)
Pre-Market: 20:00
Vertex Pharmaceuticals Total Long Term Debt (Quarterly): 0.00 for March 31, 2024
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
Date | Value |
---|---|
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.00 |
December 31, 2016 | 300.00M |
September 30, 2016 | 297.75M |
June 30, 2016 | 296.50M |
March 31, 2016 | 295.82M |
December 31, 2015 | 295.16M |
September 30, 2015 | 294.83M |
June 30, 2015 | 294.81M |
March 31, 2015 | 294.79M |
December 31, 2014 | 294.78M |
September 30, 2014 | 294.74M |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
December 31, 2013 | 0.00 |
September 30, 2013 | 0.00 |
June 30, 2013 | 0.00 |
March 31, 2013 | 400.00M |
December 31, 2012 | 400.00M |
September 30, 2012 | 400.00M |
June 30, 2012 | 400.00M |
March 31, 2012 | 400.00M |
December 31, 2011 | 400.00M |
Total Long Term Debt Definition
Total Long Term Debt is the current and non-current portion of debt that a company holds. Current Portion debt are obligations of a company lasting shorter than a year. This is found in a company's current liabilities on its balance sheet.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2019
--
Maximum
Jun 2019
--
Average
--
Median
Jun 2019
Total Long Term Debt (Quarterly) Benchmarks
Amgen Inc | 64.02B |
Eli Lilly and Co | 26.21B |
Regeneron Pharmaceuticals Inc | 1.983B |
Alpine Immune Sciences Inc | 0.00 |
Editas Medicine Inc | 0.00 |